SLC34A2 was recently identified by sera-screening as being an antigen recognised by sera from patients with immunologically ‘hot’ colorectal cancer [48] and has been shown to play a role in the chemoresistance observed in breast cancer patients [49]. Here, SLC34A2 is linked to breast carcinoma.